BeyondSpring (BYSI) Short term Debt (2015 - 2021)

BeyondSpring (BYSI) posted Short term Debt of $1.6 million for Q4 2021, up 1.1% sequentially from $1.6 million in Q3 2021.

BeyondSpring (BYSI) Short term Debt (2015 - 2021) Analysis & Trends

BeyondSpring has reported Short term Debt for 6 years, with the latest figure at $1.6 million in Q4 2021.

Quarterly Short term Debt changed N/A year-over-year to $1.6 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $1.6 million (changed N/A YoY) and the FY2021 annual result came in at $1.6 million, changed N/A from the prior year.
Short term Debt grew to $1.6 million in Q4 2021 per BYSI's latest filing, from $1.6 million in the prior quarter.
Over five years, Short term Debt peaked at $2.2 million in Q2 2021 and troughed at $2000.0 in Q2 2017.
A 4-year average of $724916.7 and a median of $205500.0 in 2019 frame the typical range for Short term Debt.
The sharpest annual moves came in 2020 and 2021: Short term Debt tumbled 95.56% in 2020, then soared 3533.33% in 2021.
Over 4 years, Short term Debt stood at $2000.0 in 2017, then jumped by 1350.0% to $29000.0 in 2019, then jumped by 110.34% to $61000.0 in 2020, then soared by 2472.13% to $1.6 million in 2021.
According to Business Quant data, Short term Debt over the past three periods registered $1.6 million, $1.6 million, and $2.2 million for Q4 2021, Q3 2021, and Q2 2021 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.84 Bn	131.99 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.48 Bn	78.49 Bn	3.93 Bn
3	Argenx Se	65.47 Bn	60.29 Bn	1.37 Bn
4	Moderna	60.15 Bn	55.01 Bn	52.00 Mn
5	BeOne Medicines	42.22 Bn	37.12 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn
7	BioNTech SE	28.54 Bn	10.14 Bn	668.28 Mn
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn
9	Royalty Pharma	27.22 Bn	26.38 Bn	-
10	BeyondSpring	29.61 Mn	29.61 Mn	-

Download Data